Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2918-2927

  Zeng, L ^a,b   Nath, C E ^b   Blair, E Y L ^a   Shaw, P J ^a,b   Stephen, K ^b   Earl, J W ^b   Coakley, J C ^b   McLachlan, A J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VALACICLOVIR;

ADOLESCENT; ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BODY SURFACE; BODY WEIGHT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EPSTEIN BARR VIRUS; GLOMERULUS FILTRATION RATE; HERPES SIMPLEX VIRUS; HUMAN; IC 50; IMMUNOCOMPROMISED PATIENT; INFANT; PRIORITY JOURNAL; STEADY STATE; VARICELLA ZOSTER VIRUS;

ACYCLOVIR; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; NEOPLASMS; PROSPECTIVE STUDIES; VALINE;

EID: 67649975596     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01138-08     Document Type: Article

References (43)

1. Balfour, H. H., Jr., B. A. Chace, J. T. Stapleton, R. L. Simmons, and D. S. Fryd. 1989. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320:1381-1387.
2. Blum, M. R., S. H. Liao, and P. de Miranda. 1982. Overview of acyclovir pharmacokinetic disposition in adults and children. Am. J. Med. 73:186-192.
3. Boeckh, M. 2006. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes 13:60-65.
4. Boeckmann, A. J., L. B. Sheiner, and S. L. Beal. 1994. NONMEM version 5.1.1 user's guide. GloboMax, Hanover, MD.
5. Bullingham, R. E., A. J. Nicholls, and B. R. Kamm. 1998. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34:429-455.
6. Bye, A. 1997. A mechanistic approach to understanding the response to antiinfectives in the population approach: measuring and managing variability in response, concentration and dose, p. 105-113. In L. Aarons (ed.), The population approach: measuring and managing variability in response, concentration and dose. COST B1 Medicine, European cooperation in the field of scientific and technical research, European Commission, Brussels, Belgium.
7. Counahan, R., C. Chantler, S. Ghazali, B. Kirkwood, F. Rose, and T. M. Barratt. 1976. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch. Dis. Child. 51:875-878.
8. de Miranda, P., and M. R. Blum. 1983. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12(Suppl. B):S29-S37.
9. Eksborg, S., N. Pal, M. Kalin, C. Palm, and S. Soderhall. 2002. Pharmacokinetics of acyclovir in immunocompromized [sic] children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med. Pediatr. Oncol. 38:240-246.
10. Englund, J. A., C. V. Fletcher, and H. H. Balfour, Jr. 1991. Acyclovir therapy in neonates. J. Pediatr. 119:129-135.
11. Ette, E. I., P. J. Williams, and J. R. Lane. 2004. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann. Pharmacother. 38:2136-2144.
12. Ette, E. I., P. J. Williams, Y. H. Kim, J. R. Lane, M. J. Liu, and E. V. Capparelli. 2003. Model appropriateness and population pharmacokinetic modeling. J. Clin. Pharmacol. 43:610-623.
13. Ette, E. I. 1997. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486-495.
14. Ette, E. I., and T. M. Ludden. 1995. Population pharmacokinetic modeling: the importance of informative graphics. Pharm. Res. 12:1845-1855.
15. Feldman, S., J. Rodman, and B. Gregory. 1988. Excessive serum concentrations of acyclovir and neurotoxicity. J. Infect. Dis. 157:385-388.
16. Feldman, S., and L. Lott. 1987. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 80:465-472.
17. Fletcher, C., and B. Bean. 1985. Evaluation of oral acyclovir therapy. Drug Intell. Clin. Pharm. 19:518-524.
18. Gill, M. J., and E. Burgess. 1990. Neurotoxicity of acyclovir in end stage renal disease. J. Antimicrob. Chemother. 25:300-301.
19. Gimenez, F., E. Foeillet, O. Bourdon, S. Weller, C. Garret, R. Bidault, and E. Singlas. 2004. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valacyclovir or acyclovir to healthy subjects. Clin. Pharmacokinet. 43:685-692.
20. Groeger, J. S., A. B. Lucas, H. T. Thaler, H. Friedlander-Klar, A. E. Brown, T. E. Kiehn, and D. Armstrong. 1993. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann. Intern. Med. 119:1168-1174.
21. Holford, N. H. G. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332.
22. Karlsson, M. O., and L. B. Sheiner. 1993. The importance of modelling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750.
23. Laskin, O. L. 1983. Clinical pharmacokinetics of acyclovir. Clin. Pharmacokinet. 8:187-201.
24. Ljungman, P., B. Lonnqvist, O. Ringden, P. Skinhoj, G. Gahrton, et al. 1989. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant. 4:613-615.
25. Mosteller, R. D. 1987. Simplified calculation of body-surface area. N. Engl. J. Med. 317:1098.
26. Nadal, D., G. Leverger, E. M. Sokal, D. Floret, Y. Perel, K. Leibundgut, and S. Weller. 2002. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J. Infect. Dis. 186(Suppl. A): S123-S130.
27. O'Brien, J. J., and D. M. Campoli-Richards. 1989. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37:233-309.
28. Parke, J., N. H. Holford, and B. G. Charles. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29.
29. Perry, C. M., and D. Faulds. 1996. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754-772.
30. Reitano, M., S. Tyring, W. Lang, C. Thoming, A. M. Worm, S. Borelli, L. O. Chambers, J. M. Robinson, L. Corey, and the International Valaciclovir HSV Study Group. 1998. Valaciclovir for the suppression of recurrent genital HSV infection: a large-scale dose range-finding study. J. Infect. Dis. 178:603-610.
31. Rubin, J. 1987. Overdose with acyclovir in a CAPD patient. Perit. Dial. Int. 7:42-43.
32. Saiag, P., D. Praindhui, C. Chastang, and the Genival Study Group. 1999. A double-blind randomized study for assessing the equivalence of valaciclovir 1000 mg once daily versus 500 mg twice daily in the early treatment of recurrent genital herpes. J. Antimicrob. Chemother. 44:525-531.
33. Saral, R., R. F. Ambinder, W. H. Burns, C. M. Angelopulos, D. E. Griffin, P. J. Burke, and P. S. Lietman. 1983. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann. Intern. Med. 99:773-776.
34. Shah, J., D. Juan, and R. Bullingham. 1994. A single dose drug interaction study of mycophenolate mofetil and acyclovir in normal subjects. J. Clin. Pharmacol. 34:1029.
35. Sheiner, L. B. 1986. Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J. Pharmacokinet. Biopharm. 14:539-555.
36. Simon, M. W., D. N. Fish, and R. G. Deeter. 2002. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. Drugs R. D. 3:365-373.
37. Soul-Lawton, J., E. Seaber, N. On, R. Wootton, P. Rolan, and J. Posner. 1995. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of aciclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39:2759-2764.
38. Spruance, S. L., S. K. Tyring, B. de Gregoris, C. Miller, K. Beutner, and the Valaciclovir HSV Study Group. 1996. A large scale, placebo-controlled, dose ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. 156:1729- 1735.
39. Tod, M., F. Lokiec, R. Bidault, F. de Bony, O. Petitjean, and Y. Aujard. 2001. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob. Agents Chemother. 45:150-157.
40. Wahlby, U., E. N. Jonsson, and M. O. Karlsson. 2002. Comparison of stepwise covariate model building strategies in population pharmacokinetic- pharmacodynamic analysis. AAPS PharmSci 4:E27.
41. Wahlby, U., E. N. Jonsson, and M. O. Karlsson. 2001. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28:231-252.
42. Weller, S., M. R. Blum, M. Doucette, T. Burnette, D. M. Cederberg, P. de Miranda, and M. L. Smiley. 1993. Pharmacokinetics of the acyclovir prodrug valacyclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595-605.
43. Zeng, L., C. E. Nath, P. J. Shaw, J. W. Earl, and A. J. McLachlan. 2008. HPLC-fluorescence assay for acyclovir in children. Biomed. Chromatogr. 22:879-887.